Evotec SE ADR Asset Resilience Ratio
Evotec SE ADR asset resilience ratio. Evotec SE ADR (EVO) has an Asset Resilience Ratio of 3.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Evotec SE ADR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Evotec SE ADR (2003–2025)
Asset resilience ratio of Evotec SE ADR from 2003 to 2025. This chart shows how Evotec SE ADR's Asset Resilience Ratio has changed over time. Read how much debt does Evotec SE ADR carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Evotec SE ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Evotec SE ADR total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $56.91 Million | 3.47% |
| Total Liquid Assets | $56.91 Million | 3.47% |
Asset Resilience Insights
- Limited Liquidity: Evotec SE ADR maintains only 3.47% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Evotec SE ADR Industry Peers by Asset Resilience Ratio
Compare Evotec SE ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Evotec SE ADR Asset Resilience Ratio by Year (2003–2025)
Evotec SE ADR asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for Evotec SE ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.25% | $57.85 Million | $1.78 Billion | -1.47pp |
| 2024-12-31 | 4.73% | $90.41 Million | $1.91 Billion | +0.67pp |
| 2023-12-31 | 4.05% | $93.20 Million | $2.30 Billion | -9.53pp |
| 2022-12-31 | 13.58% | $306.61 Million | $2.26 Billion | +6.46pp |
| 2021-12-31 | 7.12% | $159.17 Million | $2.24 Billion | +3.17pp |
| 2020-12-31 | 3.95% | $72.62 Million | $1.84 Billion | +0.45pp |
| 2019-12-31 | 3.50% | $48.25 Million | $1.38 Billion | -1.79pp |
| 2018-12-31 | 5.29% | $40.82 Million | $771.88 Million | +0.11pp |
| 2017-12-31 | 5.18% | $34.56 Million | $667.27 Million | -7.32pp |
| 2016-12-31 | 12.50% | $43.92 Million | $351.37 Million | -18.85pp |
| 2015-12-31 | 31.35% | $90.46 Million | $288.54 Million | +13.01pp |
| 2014-12-31 | 18.35% | $41.21 Million | $224.60 Million | -4.74pp |
| 2013-12-31 | 23.09% | $52.49 Million | $227.38 Million | +11.30pp |
| 2012-12-31 | 11.79% | $26.57 Million | $225.43 Million | -9.30pp |
| 2011-12-31 | 21.08% | $46.01 Million | $218.21 Million | -3.65pp |
| 2010-12-31 | 24.73% | $47.45 Million | $191.86 Million | +7.38pp |
| 2009-12-31 | 17.35% | $25.43 Million | $146.60 Million | +1.47pp |
| 2008-12-31 | 15.87% | $29.03 Million | $182.90 Million | -12.09pp |
| 2007-12-31 | 27.97% | $58.14 Million | $207.88 Million | +17.98pp |
| 2006-12-31 | 9.99% | $20.53 Million | $205.53 Million | -40.25pp |
| 2005-12-31 | 50.24% | $93.50 Million | $186.11 Million | -34.42pp |
| 2004-12-31 | 84.66% | $60.03 Million | $70.91 Million | +9.14pp |
| 2003-12-31 | 75.52% | $31.51 Million | $41.73 Million | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more